[HTML][HTML] Canakinumab in a subgroup of patients with COVID-19
C Ucciferri, A Auricchio, M Di Nicola… - The Lancet …, 2020 - ncbi.nlm.nih.gov
In a subgroup of patients, severe acute respiratory syndrome corona virus 2 (SARSCoV2)
induces a hyper inflammatory response that leads to acute respiratory dis tress syndrome. 1 …
induces a hyper inflammatory response that leads to acute respiratory dis tress syndrome. 1 …
COVID-19 cytokine storm: targeting the appropriate cytokine
RQ Cron - The Lancet Rheumatology, 2021 - thelancet.com
As of January, 2021, nearly 2-million deaths worldwide have been attributed to COVID-19,
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Much …
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Much …
First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection
L Perrot, M Hemon, JM Busnel, O Muis-Pistor… - The Lancet …, 2021 - thelancet.com
Comment www. thelancet. com/rheumatology Vol 3 January 2021 e7 before the onset of
clinical symptoms; and the presence of human leukocyte anti gen (HLA)-DR alleles that …
clinical symptoms; and the presence of human leukocyte anti gen (HLA)-DR alleles that …
[HTML][HTML] COVACTA trial raises questions about tocilizumab's benefit in COVID-19
B Furlow - The Lancet Rheumatology, 2020 - thelancet.com
Hoffmann-La Roche has announced disappointing results from its much-anticipated phase 3
COVACTA trial of tocilizumab, raising questions about the efficacy of interleukin (IL)-6 …
COVACTA trial of tocilizumab, raising questions about the efficacy of interleukin (IL)-6 …
[HTML][HTML] Anakinra in COVID-19: important considerations for clinical trials
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has caused more than 320 000 deaths as of May 19, 2020. COVID-19 deaths …
(SARS-CoV-2) has caused more than 320 000 deaths as of May 19, 2020. COVID-19 deaths …
Arthritis after SARS-CoV-2 infection
C Baimukhamedov, T Barskova… - The Lancet …, 2021 - thelancet.com
We read with interest the studies by Renaud Felten and colleagues1 and Laura Boekel and
colleagues2 published in The Lancet Rheumatology, which both contribute essential …
colleagues2 published in The Lancet Rheumatology, which both contribute essential …
Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19
Few effective therapeutic options are available for the treatment of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection. IL-6 receptor blockade has been proposed …
syndrome coronavirus 2 (SARS-CoV-2) infection. IL-6 receptor blockade has been proposed …
Preventing COVID-19-induced pneumonia with anticytokine therapy
G Monteleone, PC Sarzi-Puttini… - The Lancet …, 2020 - thelancet.com
March 23. DOI: 10.1093/ofid/ofaa105. 5 Wu C, Chen X, Cai Y, et al. Risk factors associated
with acute respiratory distress syndrome and death in patients with coronavirus disease …
with acute respiratory distress syndrome and death in patients with coronavirus disease …
Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
F Hooijberg, L Boekel, EH Vogelzang… - The Lancet …, 2020 - thelancet.com
There is a continuous debate about the risks of increased incidence of COVID-19 in
vulnerable patient groups, which includes patients with rheumatic diseases and especially …
vulnerable patient groups, which includes patients with rheumatic diseases and especially …
Viral arthritis and COVID-19
S Parisi, R Borrelli, S Bianchi, E Fusaro - The Lancet Rheumatology, 2020 - thelancet.com
The current outbreak of COVID19, caused by severe acute respiratory syndrome
coronavirus 2 (SARSCoV2), is characterised by clinical signs and symptoms such as …
coronavirus 2 (SARSCoV2), is characterised by clinical signs and symptoms such as …